This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CE Pharm 2017: Roundtable Discussions
Share |

 

Roundtable Topics

The Roundtable Session will take place on Tuesday, September 19, 2017 from 5:00 PM to 6:00 PM.  See below for a list of the table topics and to view the abstracts.


 

Table 1: What Are Opportunities and Challenges for Further Implementation of CE-MS (including Chip-MS) in Development of Biopharmaceuticals?
Facilitator: Mei Han, Amgen Inc.
Scribe: Zoran Sosic, Biogen

To view the table abstract and discussion notes, click here.


 

Table 2: CE in Formulation Development Support and Stability Analytics
Facilitator: Ewoud van Tricht,  Janssen Infectious Diseases and Vaccines  
Scribe 
Guinevere Kammeijer, Leiden University Medical Center

To view the table abstract and discussion notes, click here.


 

Table 3: Chip Based Separations vs Classical CE Separations: Advantages & Disadvantages Comparing Platforms and Approaches
Facilitator
: Nomalie Jaya, Seattle Genetics, Inc. 
Scribe: Claudia Michael, Solvias AG

To view the table abstract and discussion notes, click here.


 

Table 4: Reduced and Non-reduced CE-SDS for Antibodies. When to Eliminate One Versus the Other?
Facilitator: Henry Luo, Regeneron Pharmaceuticals
Scribe: 
Bernd Moritz, F. Hoffman - La Roche Ltd.  

To view the table abstract and discussion notes, click here.


 

Table 5: Applications of CE to Nucleic Acid Analysis
Facilitator: Richard Rustandi, Merck & Co, Inc.
Scribe: Kelsey Dent, Genentech, a Member of the Roche Group

To view the table abstract and discussion notes, click here.


 

Table 6: Instrument Quality, Reliability, and Failure Rate
Facilitator: Hermann Wätzig, University of Braunschweig   
Scribe: Stefanie Wohlrab, Roche Diagnostics GmbH 

To view the table abstract and discussion notes, click here.


 

Table 7: What Are the Most Challenging Separation/Identification Problems Now (e.g. Subvisible Particles) and How Does CE Fit In?
Facilitator: Joshua Woods, Pfizer, Inc.
Scribe: Yunan Wang, Amgen Inc.

To view the table abstract and discussion notes, click here.


 

Table 8: Trends in Pharmaceutical Application of CE
Facilitator: Maria Schwartz, Solvias AG

Scribe: Nathan Lacher, Pfizer, Inc.  

To view the table abstract and discussion notes, click here.


 

Table 9: Hot Topic 
CE Profiling: Methodologies and Tools for Enabling Peak Identification and Characterization

Facilitator: David Michels, Genentech, a Member of the Roche Group 
Scribe: Tim Blanc, Eli Lilly & Company 
   

To view the table abstract and discussion notes, click here.


 

Table 10: Hot Topic
Analytical Strategies for Expedited Application Programs – Demands and Solutions

Facilitator: Joel Welch, CDER, FDA   
Scribe: Steffen Kiessig, F. Hoffmann - La Roche Ltd. 

To view the table abstract and discussion notes, click here.


 

 

 

 

 

 

 

 

 


 

more Calendar

1/28/2019 » 1/31/2019
CMC Strategy Forum and WCBP 2019

1/29/2019 » 1/31/2019
WCBP 2019 Live Stream

3/12/2019 » 3/13/2019
CMC Strategy Forum Latin America 2019

Featured Members
William Weiss, Eli Lilly and CompanyFind out more about Will in this month's Member Spotlight!

Membership Software Powered by YourMembership  ::  Legal